AstraZeneca PLC (AZN) Claims Neuroscience Shake-Up is Paying Off ; May Advance at Least 8 Drugs to Final Tests by 2015  
7/13/2012 8:07:23 AM

AstraZeneca says that its move to cut its 800-900 neuroscience staff and adopt a virtual external research unit of about 40 scientists is already bearing fruit. AstraZeneca Plc (AZN) aims to advance at least eight medicines into late-stage tests within three years, one of its top research and development executives said today. “We’ve set our R&D organization a goal of delivering eight to 11 Phase 3 projects,” Menelas N. Pangalos, executive vice president of the company’s Innovative Medicine Research Units, told reporters at a briefing in London. “That’s more than we’ve ever done and that’s going to make us more competitive in terms of our peer group,” Pangalos said. For more information, please click on Pharma Times' link below.